Nanotechnology: a new immuno-onocology weapon
This article outlines three innovative studies that use nanotechnology to deliver a new immunotherapy approach towards cancers.
List view / Grid view
This article outlines three innovative studies that use nanotechnology to deliver a new immunotherapy approach towards cancers.
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
In this ebook are articles on immune checkpoint inhibitors and enhancing CAR T-cell therapies.
A new Drug Target Review issue is now ready to download! This issue features articles which explore how artificial intelligence can enhance screening and ways to find new hits through simultaneous orthogonal screens. Also included are articles on CRISPR, immuno-oncology and RSV vaccines.
University of Pittsburgh researchers have designed cancer-fighting nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy
US researchers discovered in a study in mice that augmented drug eliminates cancer cells without causing toxicity.
US researchers find that bacteria could help tumours progress and resist treatment.
US researchers have utilised a cancer immunotherapy technique, CAR-T cell method to effectively eliminate SARS-CoV-2 virus pre- and post-infection in vitro.
Sloan Kettering Institute (SKI) researchers have developed a new machete technique to slice into the cancer genome and study copy number alterations.
This article highlights five of the latest findings revealed using CRISPR that could be used in the development or design of new therapies.
Researchers have developed a new method for comparing CAR T cells, each with slightly different molecular features, to determine which is most effective and long-lasting against cancer.
A new pre-clinical study has utilised nanoparticles to attach immune-activating molecules to cancer cells.
NIH researchers who intravenously delivered a cancer vaccine to mice report that it increased the number of T cells able to combat tumours.
US scientists have found strong evidence for testing VCU-manufactured drugs in liver cancer.
Using DNA barcoding to track cancer cells through time, scientists have shown that the cells have diverse abilities to escape the immune system.